Insulin Resistance
Conditions
Keywords
Propolis
Brief summary
Propolis, a natural resinous mixture rich in polyphenols, produced by bees from a variety of plant sources, has shown significant therapeutic effects and may prevent the development of certain chronic diseases. Current evidence supports the beneficial effect of these bioactive phytochemicals on the management of type 2 diabetes mellitus (T2DM) and other chronic diseases. The objective of this study is to evaluate the effect of poplar propolis extract powder (PPEP) on glucose homeostasis and other clinical parameters in insulin-resistant patients (diagnosed by HOMA-IR index \> 1.85 for men and \> 2.07 for women).
Detailed description
Backgroud: Propolis, a natural resinous mixture rich in polyphenols, produced by bees from a variety of plant sources, has shown significant therapeutic effects and may prevent the development of certain chronic diseases. Current evidence supports the beneficial effect of these bioactive phytochemicals on the management of type 2 diabetes mellitus (T2DM) and other chronic diseases. The objective of this study is to evaluate the effect of poplar propolis extract powder (PPEP) on glucose homeostasis and other clinical parameters in insulin-resistant patients (diagnosed by HOMA-IR index \> 1.85 for men and \> 2.07 for women). Methods: The trial was a randomized, controlled, crossover, intervention study. Insulin-resistant patients (n=9) (8 women, 1 man), with a mean ± SD age 49 ± 7, were subjected to two periods of supplementation (propolis and placebo) for 3-months, separated by a 2-week washout period. The quantity of propolis administered was determined individually to reach 6 mg of polyphenols/kg. Fasting blood test and oral glucose tolerance test (OGTT) were performed before and after each treatment.
Interventions
DIETARY_SUPPLEMENTPropolis
Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols. Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase. The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed.
DIETARY_SUPPLEMENTPlacebo
Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice. Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase. The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed.
Sponsors
Assistance Publique Hopitaux De Marseille
Aix Marseille Université
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
The present trial was a randomized, double-bind, controlled, crossover, dietary intervention study. During this trial, two types of supplementations were randomly administered during two treatment periods (propolis and placebo), using a random number table. The placebo served as the reference group for comparison. Participants and caregivers were blinded to the type of treatment consumed.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Body mass index (BMI) ≥ 30 kg/m2 * Insulin resistance defined as a HOMA-IR index \> 1.85 for men and \> 2.07 for women
Exclusion criteria
* Presence of diabetes * Recent weight change (≥ 5% in the last 3 months) * Documented allergy to bee products and/or fish products * Positive serology for human immunodeficiency virus or hepatitis * High blood pressure * Elevated transaminases (AST \> 40 IU/L ; ALT \> 45 IU/L) * Low creatine clearance (estimated glomerular filtration rate \< 90 ml/min) * Interfering treatment (cholesterol-lowering treatment, intestinal absorption modulating treatment, absorption modulating treatment and/or insulin sensitivity) * Gastrointestinal tract surgery * Pregnancy and / or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Matsuda-DeFronzo Insulin Sensitivity Index (ISI-M) | 3 months | The primary outcome was change in the Matsuda-DeFronzo Insulin Sensitivity Index (ISI-M) at the end of supplementation. The ISI-M is calculated by the following formula: 10,000 / square root \[(Glu0 × Ins0) × (Glumean OGTT × Insmean OGTT)\], where Glux and Insx represent plasma glucose (mg/dL) and insulin values (UI/L), respectively, at time x min during. The ISI-M index, proposed by Matsuda and Defronzo, makes it possible to estimate insulin sensitivity derived from the OGTT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in 8-iso-prostaglandin F2α levels | 3 months | Enzymatic determination of 8-iso-prostaglandin F2α (8-iso-PGF 2α) (pg/mL). |
| Change in creatinine levels | 3 months | Enzymatic determination of creatinine (mg/L). |
| Change in glucose homeostasis | 3 months | Glycaemia at T0, T30, T60, T90 and T120 (mmol/L) mesured after after an oral glucose tolerance test (OGTT). |
| Change in insulin homeostasis | 3 months | Insulinemia at T0, T30, T60, T90 and T120 (mUI/L) mesured after after an oral glucose tolerance test (OGTT). |
| Change in triglyceride levels | 3 months | Enzymatic assay by spectrophotometry of triglycerides (mmol/L). |
| Change in cholesterol levels | 3 months | Enzymatic assay by spectrophotometry of cholesterol (mmol/L). |
| Change in high density lipoprotein (HDL) cholesterol levels | 3 months | Enzymatic assay by spectrophotometry of HDL cholesterol (mmol/L). |
| Change in low density lipoprotein (LDL) cholesterol levels | 3 months | Friedewald formula : LDL=cholesterol-HDL-(triglyceride/2,2) expressed in mmol/L. |
| Change in glycated hemoglobin A1c (HbA1c) levels | 3 months | HbA1c mass spectrometry assay (%). |
| Change in gamma glutamyl transferases (GGT) | 3 months | Enzymatic determination of gamma glutamyl transferases (GGT) (UI/L). |
| Change in body mass index (BMI) | 3 months | BMI calculated by weight (kg) / size (m) squared. |
| Change in body fat rate | 3 months | Fat mass rate estimated by impedancemetry (DEXA) (%). |
| Change in body lean rate | 3 months | Lean mass rate estimated by impedancemetry (DEXA) (%). |
| Change in C-reactive protein | 3 months | Enzymatic determination of CRP (mg/L). |
| Change in transaminases levels | 3 months | Enzymatic determination of alanine aminotransferase (ALAT) and aspartate aminotransférase (ASAT) (UI/L). |
| Change in creatinine clearance | 3 months | Estimation of creatinine clearance (mL/min) by formula : 1,23 (for men) or 1,04 (for women) x weight (kg) x (140 - age)/creatinine (mg/L). |
| Change in leptin levels | 3 months | Enzymatic determination of leptin (pg/mL). |
| Change in adiponectin levels | 3 months | Enzymatic determination of adiponectin (ng/mL). |
| Change in weight | 3 months | Weight measurement by scale (kg). |
Countries
France
Outcome results
None listed